- Guardant Health (GH, Financial) reveals findings from the largest study on molecular residual disease (MRD) in colon cancer.
- The Guardant Reveal™ test can predict disease recurrence and survival rates, influencing treatment decisions.
- Study results were presented at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting.
Guardant Health, Inc. (GH), a leader in precision oncology, together with its research collaborators, announced groundbreaking results from the largest study to date on circulating tumor DNA (ctDNA) in colon cancer. The study highlights the efficacy of the Guardant Reveal™ test in assessing the risk of disease recurrence and survival rates, thereby aiding critical treatment decisions post-surgery.
This Phase III trial involved over 2,000 patients with stage III colon cancer and featured a median follow-up period of 6.1 years. The research was showcased at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting. Findings suggest that ctDNA detected in the bloodstream after cancer surgery, but before starting adjuvant therapy, is a strong predictor of disease recurrence and less favorable survival outcomes.
The study showed that 62.6% of patients with detectable post-surgical ctDNA experienced cancer recurrence within three years, despite undergoing adjuvant chemotherapy. In contrast, only 15.4% of patients with undetectable ctDNA faced recurrence during the same timeframe. The data support the routine use of ctDNA testing for better patient management, guiding oncologists towards more informed treatment choices.
"Thirty percent of stage III colon cancer patients relapse post-surgery despite adjuvant chemotherapy," noted Dr. Frank Sinicrope from Mayo Clinic. "This study proves that post-surgical ctDNA analysis can enhance the prediction of disease recurrence, improving patient management over standard criteria."
Helmy Eltoukhy, Guardant Health's chairman and co-CEO, added, "The study confirms the Guardant Reveal test's capability to identify high-risk patients, enabling oncologists to make informed therapeutic decisions, enhancing patient outcomes."
About Guardant Health: Guardant Health is a prominent precision oncology company focusing on innovative blood and tissue tests to transform patient care and expedite the development of new cancer treatments. Their technology supports all cancer care stages, from early detection to recurrence monitoring and treatment selection.
